Whan In Pharm Co.,Ltd. (KRX:016580)
South Korea · Delayed Price · Currency is KRW 10,390
-140 (-1.33%)
Apr 2, 2026, 3:30 PM KST
Whan In Pharm Income Statement
Financials in millions KRW. Fiscal year is January - December.
Millions KRW. Fiscal year is Jan - Dec.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Operating Revenue | 255,214 | 259,596 | 230,394 | 198,935 | 177,776 |
Other Revenue | -0 | - | - | -0 | -0 |
| 255,214 | 259,596 | 230,394 | 198,935 | 177,776 | |
Revenue Growth (YoY) | -1.69% | 12.68% | 15.81% | 11.90% | 3.54% |
Cost of Revenue | 168,811 | 165,931 | 131,451 | 100,277 | 84,416 |
Gross Profit | 86,404 | 93,665 | 98,943 | 98,658 | 93,359 |
Selling, General & Admin | 67,932 | 67,564 | 64,470 | 61,948 | 55,849 |
Research & Development | 1,217 | 771.13 | 1,072 | 3,331 | 2,659 |
Amortization of Goodwill & Intangibles | 262.86 | 255.99 | 194.22 | 418.32 | 383.22 |
Other Operating Expenses | 1,365 | 1,300 | 1,311 | 1,273 | 1,238 |
Operating Expenses | 73,385 | 72,170 | 68,772 | 68,847 | 62,083 |
Operating Income | 13,019 | 21,495 | 30,170 | 29,810 | 31,276 |
Interest Expense | -28.77 | -23.12 | -22.66 | -51.88 | -51.55 |
Interest & Investment Income | 2,092 | 2,971 | 3,769 | 2,500 | 1,821 |
Earnings From Equity Investments | -199.72 | 1,981 | -1,006 | -201.08 | -61.86 |
Currency Exchange Gain (Loss) | 82.09 | -69.24 | -141.12 | 343.44 | 223.56 |
Other Non Operating Income (Expenses) | 243.21 | 528.81 | 1,016 | 153.71 | 329.1 |
EBT Excluding Unusual Items | 15,208 | 26,884 | 33,785 | 32,555 | 33,536 |
Gain (Loss) on Sale of Investments | - | 392.98 | 1,895 | 925.83 | 794.08 |
Gain (Loss) on Sale of Assets | -281.59 | -330.11 | -1,160 | -1,897 | -6.22 |
Asset Writedown | - | - | -726.43 | -1,776 | -442.01 |
Pretax Income | 14,926 | 26,947 | 33,793 | 29,808 | 33,882 |
Income Tax Expense | 1,331 | 3,566 | 4,019 | 6,075 | 7,423 |
Earnings From Continuing Operations | 13,595 | 23,381 | 29,774 | 23,734 | 26,459 |
Minority Interest in Earnings | - | - | - | 187.76 | 201.09 |
Net Income | 13,595 | 23,381 | 29,774 | 23,921 | 26,660 |
Net Income to Common | 13,595 | 23,381 | 29,774 | 23,921 | 26,660 |
Net Income Growth | -41.85% | -21.47% | 24.47% | -10.27% | 13.99% |
Shares Outstanding (Basic) | 16 | 15 | 15 | 15 | 15 |
Shares Outstanding (Diluted) | 16 | 15 | 15 | 15 | 15 |
Shares Change (YoY) | 3.86% | - | - | - | - |
EPS (Basic) | 857.41 | 1531.45 | 1950.23 | 1566.86 | 1746.22 |
EPS (Diluted) | 857.41 | 1531.45 | 1950.23 | 1566.86 | 1746.00 |
EPS Growth | -44.01% | -21.47% | 24.47% | -10.26% | 13.98% |
Free Cash Flow | 6,194 | -6,664 | -7,334 | -16,799 | 30,931 |
Free Cash Flow Per Share | 390.61 | -436.48 | -480.39 | -1100.32 | 2025.98 |
Dividend Per Share | - | 300.000 | 300.000 | 300.000 | 300.000 |
Gross Margin | 33.86% | 36.08% | 42.95% | 49.59% | 52.52% |
Operating Margin | 5.10% | 8.28% | 13.10% | 14.99% | 17.59% |
Profit Margin | 5.33% | 9.01% | 12.92% | 12.03% | 15.00% |
Free Cash Flow Margin | 2.43% | -2.57% | -3.18% | -8.44% | 17.40% |
EBITDA | 22,883 | 29,970 | 36,830 | 34,657 | 35,478 |
EBITDA Margin | 8.97% | 11.54% | 15.99% | 17.42% | 19.96% |
D&A For EBITDA | 9,865 | 8,475 | 6,659 | 4,847 | 4,202 |
EBIT | 13,019 | 21,495 | 30,170 | 29,810 | 31,276 |
EBIT Margin | 5.10% | 8.28% | 13.10% | 14.99% | 17.59% |
Effective Tax Rate | 8.92% | 13.23% | 11.89% | 20.38% | 21.91% |
Advertising Expenses | 8,887 | 15,285 | 12,359 | 10,387 | 9,519 |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.